一品红在研痛风创新药氘泊替诺雷（AR882）国内Ⅲ期临床试验已入组超过50%的受试者

Core Viewpoint - Yipinhong (300723) has successfully enrolled over 50% of participants in the Phase III clinical trial for its innovative gout treatment, Deuterated Parnate (AR882) [1] Group 1: Company Overview - Yipinhong is developing Deuterated Parnate (AR882), a potent and highly selective URAT1 inhibitor aimed at promoting urate excretion and lowering serum uric acid (sUA) levels [1] Group 2: Clinical Trial Progress - The Phase III clinical trial for Deuterated Parnate (AR882) has surpassed the 50% enrollment mark for participants [1]